Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02500316 · ClinicalTrials.gov registry record · Phase 2
Long Term Follow up Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children
A Phase 2 study of Growth Hormone Deficiency (GHD), sponsored by OPKO Health.
- Completed
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
- 13
- Study locations
NCT02500316 is a Phase 2 study of Growth Hormone Deficiency (GHD) that has completed, run by OPKO Health. The registered enrollment target is 48 participants. The trial reports 13 study locations across 2 states.
The verdict
NCT02500316, a Phase 2 study of Growth Hormone Deficiency (GHD), has completed, sponsored by OPKO Health.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
- 13
- Study locations
Study Summary
Protocol CP-4-004-OLE (Open Label Extension) is designed as a long-term, open-label extension using single patient use, multi-dose, disposable pre-filled pen.
Conditions Studied
Interventions
- DRUG MOD-4023
Study Locations (13)
Other
- 2DKB - Minsk
- Children's Hospital "P. A. Kyriakou" - Athens
- Buda Children's Hospital - Budapest
- Endocrinology Scientific Centre, Institute of Child Endocrinology - Moscow
- Russian Medical Academy of Postgraduate Education - Moscow
- SPGPMA - Saint Petersburg
- SamGMU - Samara
- SBEIHPE - Ufa
- Donetsk Regional Children Clinical Hospital - Donetsk
- Institute of Endocrinology - Kiev
- Ukrainian Scientific Center of Endocrine Surgery Moh of Ukraine - Kiev
- Odessa Regional Children'S Clinical Hospital - Odesa
Florida
- Nemours Children's Clinic - Jacksonville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2014-02 |
| Est. Completion | 2023-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02500316
The ClinicalTrials.gov registry entry for NCT02500316 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is OPKO Health, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Growth Hormone Deficiency (GHD) appearing as the primary indexed condition, and to 1 intervention - of which MOD-4023 is the first listed.
NCT02500316 reports 13 study locations spanning 2 distinct geographic areas - top geographies include Other, Florida.
Frequently Asked Questions
What is clinical trial NCT02500316 about?
NCT02500316 is a clinical study titled "Long Term Follow up Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children". Protocol CP-4-004-OLE (Open Label Extension) is designed as a long-term, open-label extension using single patient use, multi-dose, disposable pre-filled pen.
What is the current status of trial NCT02500316?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2014-02. Estimated completion is 2023-11.
What conditions does trial NCT02500316 study?
This clinical trial studies the following conditions: Growth Hormone Deficiency (GHD).
What interventions are being tested in trial NCT02500316?
The interventions under investigation include: MOD-4023 (DRUG).
Who is sponsoring clinical trial NCT02500316?
This trial is sponsored by OPKO Health, which has 32 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02500316 being conducted?
This trial has 13 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Growth Hormone Deficiency (GHD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.